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Primary focal segmental glomerulosclerosis (FSGS) accounts for nearly 10 % of patients who require renal
replacement therapy. Elevated circulating levels of soluble urokinase receptor (suPAR) have been identified as a
biomarker to discriminate primary FSGS from other glomerulopathies. Subsequent reports have questioned the
diagnostic utility of this test. In a study in BMC Medicine, Huang et al. demonstrate that urinary soluble urokinase
receptor (suPAR) excretion assists in distinguishing primary FSGS from other glomerular diseases, and that high
plasma suPAR concentrations are not directly linked to a decline in glomerular filtration rate (GFR). This observation
suggests that further investigation of suPAR is warranted in patients with FSGS. It should be interpreted in light of a
recent report that B7-1 is expressed in the podocytes of a subset of patients with FSGS, and that blocking this
molecule may represent the first successful targeted intervention for this disease. These advances highlight the
rapid pace of scientific progress in the field of nephrology. Nephrologists should work together, share resources,
and expedite the design of protocols to evaluate these novel biomarkers in a comprehensive and scientifically valid
manner.
Please see related article http://www.biomedcentral.com/1741-7015/12/81.
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There appears to be a basic drive in human beings to try to
become members of teams. It is part of our nature as social
animals to define ourselves based on our self-perception of
who we are and how we differ from those outside our
group [1]. Doctors do not change their stripes just because
two letters are added to their name after 4 years of medical
training, and they are hard-wired, like all people, to join
groups. There are large teams such as surgeons, internists,
and psychiatrists, and smaller teams such as nephrologists.
Within nephrology, there are other sub-identities from
which people can choose, such as transplant nephrologist,
hypertension specialist, or geriatric nephrologist.
In the past, members of the glomerular team constituted
a small cohesive group of specialists who labored hard
in the care of patients with glomerular disease. They
were fairly unified because there was not too much to
splinter the group. The pathophysiology of glomerular
disease remained a black box, and therapeutic options
were limited. Perceived differences were not sufficient
to start a new team.Correspondence: howard.trachtman@nyumc.org
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2014However, if you have an interest in glomerular disease,
then these are very exciting times. Whole exome sequen-
cing, enhanced interaction with other disciplines, improve-
ments in experimental techniques, expanded bioinformatics
capacity, and development of systems biology approaches
have resulted in dramatic advances in our understanding of
how the glomerulus functions in health and disease [2]. A
predictable consequence of these striking discoveries is the
emergence of teams of devotees who promote the import-
ance of particular mediators of disease or potential thera-
peutic interventions, to the exclusion of other approaches.
That is what being a member of the team means.
The story of the association between elevated circulating
levels of soluble urokinase receptor (suPAR) as a potential
marker of primary focal segmental glomerulosclerosis
(FSGS) is a vivid illustration of this social phenomenon.
FSGS is an important cause of glomerular disease in
children and adults, and accounts for nearly 10% of patients
who develop end stage kidney disease. Moreover, the
disease can recur in nearly 25% of patients who undergo
kidney transplantation [3]. These clinical features emphasize
the compelling need to distinguish FSGS from other
forms of glomerular disease. Although suPAR has been
recognized for many years as a marker of inflammationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scene in 2011, when Jochen Reiser’s group reported that
a high plasma concentration of this biomarker indicated
the presence of primary FSGS versus other forms of
primary glomerular disease [8]. suPAR was associated
with recurrent glomerular disease after kidney transplant-
ation. Moreover, the molecule appeared to be more than
simply an epiphenomenon in FSGS, because in vitro studies
indicated that suPAR binds to β3 integrin in the podocyte
membrane, activates intracellular signaling, promotes
foot process effacement, and disrupts glomerular bar-
rier function, leading to proteinuria [7]. This exciting
observation was followed by several supportive reports
[9-11]. However, over the past year there have been six
reports from various cohorts of patients with FSGS and
other glomerular diseases indicating that plasma suPAR
concentration does not discriminate FSGS from other
glomerular diseases, and that the primary determinant
of the suPAR level may be the glomerular filtration rate
(GFR) [12-17].
Can suPAR distinguish FSGS from other glomerular diseases?
It is in this context that the report of Huang et al. [18]
in BMC Medicine should be read. In their series of pa-
tients with primary glomerular disease, urinary suPAR
excretion was significantly higher in patients with primary
FSGS (n = 62) compared with all other varieties of glom-
erular disorders. The cellular variant of FSGS was asso-
ciated with higher urinary levels than other subtypes,
and the excretion correlated with proteinuria in all forms.
Urinary suPAR excretion fell in response to effective ther-
apy. The urinary suPAR excretion was biologically active
because it induced AP5 expression in cultured human
podocytes. The robust findings in this article support the
relevance of suPAR as a contributing factor in the patho-
genesis of primary FSGS in patients with a preserved GFR.
It is consistent with a report that higher urinary suPAR
excretion may identify patients with recurrent FSGS in
their transplanted kidney [19]. The strengths of this study
are the large patient sample, a meaningful approach to
distinguishing primary from secondary FSGS based on
the extent of epithelial cell foot process effacement,
and the incorporation of studies to demonstrate the
in vitro activity of urinary suPAR. The limitations should
be acknowledged, and include a lack of studies to assess
stability of suPAR in the urine, an inability to distinguish
between various subtypes of suPAR based on processing
of the molecule, and lack of long-term follow-up [20].
Nonetheless, the study allows assessment of suPAR to be
performed routinely in a readily accessible body fluid that
may reflect intra-renal effects more closely than changes
in the plasma concentration. It is likely that the members
of the suPAR team will be heartened by this report, while
the skeptics will express concern about the adequacy ofmethods used to measure suPAR in the urine and the
criteria that were applied to categorize the patients.
Are other factors causal in FSGS?
There is another exciting recent discovery that is also
driving those in the nephrology field to join competing
teams. It represents the identification of another factor
that might be causal in FSGS, and which could be used
both for diagnosis and targets for therapy. Yu et al.
[21] recently described five patients (four with recur-
rent FSGS after kidney transplantation and one with
FSGS in native kidneys) who were treated with abatacept
(cytotoxic T-lymphocyte–associated antigen 4–immuno-
globulin fusion protein [CTLA-4–Ig]) based on positive
staining for B7-1 in glomerular podocytes. All five pa-
tients experienced a clinically significant reduction in
proteinuria. This has prompted a surge in the abatacept
club membership. However, within 4 months, two brief
reports have appeared questioning the validity of these
findings, and suggesting that the B7-1 pathway is not ac-
tive in glomerular disease and is not a therapeutic target
[22,23]. The community is splitting up into teams: those
who consider suPAR, B7-1, or other favorite candidates to
be the main causal factor for FSGS.
Conclusions
The current position of suPAR in the setting of glomeru-
lar disease has been succinctly summarized in a recent,
balanced editorial commentary [24]. Editorials on B7-1
will follow in short order. Rather than simply rehearse
arguments that have already been made in the literature,
I will address the following open question: will the pres-
sure to join nephrology teams interfere with a rational
and comprehensive evaluation of these new pathways in
the pathogenesis of FSGS and other glomerular diseases?
What is the thoughtful nephrologist to do in this chal-
lenging era of enormous growth in the knowledge base
for glomerular disease? I suggest we should applaud
the innovative efforts of clinical scientists such as Jochen
Reiser and Peter Mundel, who are uncovering novel
pathways in the development of kidney disease. It would
seem prudent to maintain the glomerular disease team
as a large inclusive club that welcomes all comers.
Membership should be defined by a commitment to
rigorously study newly identified biomarkers and valid-
ate disease targets in well-designed clinical trials. The
efforts of investigators such as Huang should be ana-
lyzed carefully by Team Nephrology, and added to the
mix as the community works to clarify the value and
utility of new discoveries like suPAR and B7-1. Fortunately,
the scientific advances are being reinforced by the creation
of a stable infrastructure to promote ongoing evaluation
of new biomarkers and novel therapies for glomerular
disease. The National Institute of Diabetes and Digestive
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strong commitment to improving the outcomes for patients
with primary glomerular disease by investing vital resources
in establishing the Nephrotic Syndrome Study Network
(NEPTUNE) and Cure Glomerulonephropathy (CureGN)
prospective cohort studies [25]. Research in glomerular dis-
ease is moving forward on all fronts. For nephrologists,
Charles Dickens had it wrong. It is the best of times, it is
an age of wisdom, it is a season of light, it is a spring of
hope, and we have everything before us.
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